Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 63-67

  Lebret, Thierry ^a   Bohin, Denis ^a   Kassardjian, Zareh ^a   Herve, Jean Marie ^a   Molinie, Vincent ^a   Barre, Philippe ^a   Lugagne, Pierre Marie ^a   Botto, Henry ^a  

^a FOCH HOSPITAL   (France)

Author keywords

Bladder; Carcinoma; Immunotherapy; Mycobacterium bovis; Transitional cell

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

EID: 0033992030     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67973-6     Document Type: Article

References (30)

1. Herr, H. W., Wartinger, D. D., Fair, W. R. et al: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol, 147: 1020, 1992.
2. Herr, H. W., Schwalb, D. M., Zhang, Z.-F. et al: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol, 13: 1404, 1995.
3. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol, 116: 180, 1976.
4. Kiemeney, L. A. L. M., Witjes, J. A., Heijbroek, R. P. et al: Predictability of recurrent and progressive disease in individual patients with primary bladder cancer. J Urol, 150: 60, 1993.
5. Birch, B. R. P. and Harlands, S. J.: The pT1 G3 bladder tumour. Br J Urol, 64: 109, 1989.
6. Eure, G. R., Cundiff, M. R. and Schellhammer, P. F.: Bacillus Calmette-Guërin therapy for high risk stage T1 superficial bladder cancer. J Urol, 147: 376, 1992.
7. Cookson, M. S. and Sarosdy, M. F.: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol, 148: 797, 1992.
8. Pansadoro, V., Emiliozzi P., Defidio, D. et al.: Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long term results. J Urol, 154: 2054, 1995.
9. Lebret, T., Gaudez, F., Hervé, J. M. et al: Low-dose BCG instillation in the treatment of stage T1 grade G3 bladder tumours: recurrence, progression and success. Eur Urol, 34: 67, 1998.
10. Chen, S. S., Chen, K. K., Lin, A. T. L. et al: The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder. Br J Urol, 78: 209, 1996.
11. Holmäng, S., Hedelin, H., Aderström, C. et al: The relationship among multiple recurrences, progression and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol, 153: 1823, 1995.
12. Gilbert, H. A., Logan, J. L., Kagan, A. R. et al: The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J Urol, 119: 488, 1978.
13. Torti, F. M. and Lum, B. L.: The biology and treatment of superficial bladder cancer. J Clin Oncol, 2: 505, 1984.
14. Lutzeyer, W., Rübben, H. and Dahm, H.: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol, 127: 250, 1982.
15. Norming, U., Tribukait, B., Nyman, C. R. et al: Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J Urol, 148: 1420, 1992.
16. Norming, U., Tribukait, B., Gustafson, H. et al: Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J Urol, 147: 11, 1992.
17. Heney, N. M., Ahmed, S., Flanigan, M. J. et al: Superficial bladder cancer: progression and recurrence. J Urol, 130: 1083, 1983.
18. Summers, J. L., Falor, W. H. and Ward, R.: A 10-year analysis of chromosomes in non-invasive papillary carcinoma of the bladder. J Urol, 125: 177, 1981.
19. Torti, F. M., Lum, B. L., Aston, D. et al.: Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol, 5: 125, 1987.
20. Prout, G. R., Jr., Barton, B. A., Griffin, P. P. et al: Treated history of non invasive Grade 1 transitional cell carcinoma. J Urol, 148: 1413, 1992.
21. Mulders, P. F. A., Hoekstra, W. J., Heybroek, R. P. M. et al: Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Baldder Cancer Study Group. Eur J Cancer, 30A: 914, 1994.
22. Hurle, R., Losa, A., Ranieri, A. et al: Low dose Pasteur Bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J Urol, 156: 1602, 1996.
23. Thompson, R. A., Jr., Campbell, E. W., Kramer, H. C. et al: Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol, 149: 1010, 1993.
24. Lacombe, L., Dalbagni, G., Zhang, Z. F. et al: Overexpression of P53 protein in high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol, 14: 2646, 1996.
25. Lebret, T., Becette, V., Barbag latta, M. et al: Correlation between p53 over expression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol, 159: 788, 1998.
26. Zlotta, A. R., Noel, J.-C., Fayt, I. et al: Correlation and prognostic significance of p53, p21 WAFI/CIPI and Ki67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guérin intravesical therapy. J Urol, 161: 792, 1999.
27. Malmström, P. U., Bush, C. and Norlen, B. J.: Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol, 21: 185, 1987.
28. Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am, 19: 573, 1992.
29. Vegt, P. D. J., Witjes, J. A., Witjes, W. P. J. et al: A randomized study of intravesical mitomycin C, bacillus Calmette-Guérin Tice and bacillus Calmette-Guérin RIVM treatment in pTa-T1 papillary carcinoma and carcinoma in situ of the bladder. J Urol, part 2, 153: 929, 1995.
30. Obek, C., Shelfo, S. W., Korman, H. J. et al: Intravesical therapy for transitional cell carcinoma of the bladder: the community practice. Urology, 53: 82, 1999.